How do I buy Merck (MRK) stock?

Buying Merck (MRK) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "MRK", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy MRK by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if MRK is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Merck (MRK) Stock

Q: What is the minimum investment for MRK on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Merck from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · MRK

Trade MRK

Key stats

Market cap: $356.93B
Price / Earnings ratio: 112.5x
EPS (TTM): $1.27
Volume: Loading
52-week high: $156.92
52-week low: $82.01
Dividend yield: 2.26%
Dividend amount (latest): $0.85
EPS vs analyst estimate: +9.8%Q3 FY25 · $2.58 vs $2.35

Source: third-party data provider, as of November 5, 2026

EPS estimate: analyst consensus

Compare with MRK

Technical indicators

RSI 14: 56.69
MACD 12/26/9: 0.58
EMA 9 of MACD: 0.15
MACD histogram: 0.42
SMA 50: $146.54; Price above SMA 50
EMA 50: $144.05; Price above EMA 50
SMA 200: $127.28; Price above SMA 200
EMA 200: $127.97; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 17 analyst ratings

Strong Sell0

Sell0

Hold4

Buy13

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2022

2023

2024

2025

78B51B26B0

Debt & Balance Sheet

Total assets

Total liabilities

2022

2023

2024

2025

164B108B54B0

Revenue to Profit

2025

$65.0B

Revenue

$0.0

Cost of revenue

$48.6B

Gross profit

$0.0

Operating expenses

$18.3B

Net income

Earnings

EPS forecast

Actual EPS

$2.58

$2.35

Q3FY25

$2.06

Q4FY25

$1.82

Q1FY26

$2.12

Q2FY26

$2.43

Q3FY26

The market is expecting earnings per share of $2.43 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Merck

For more than 125 years, Merck (known as MSD outside of the U.S. and Canada) has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.

SectorHealthcare

IndustryDrug Manufacturers - General

Employees73,000

CEOMr. Robert M. Davis J.D.

IPO DateJan 13, 1978

HeadquartersRahway, NJ

Key Executives

Name	Title	Year Born
Mr. Robert M. Davis J.D.	Chairman, President & CEO	1967
Ms. Caroline A. Litchfield	Executive VP & CFO	1969
Ms. Jennifer L. Zachary J.D.	Executive VP & General Counsel	1978
Dr. Dean Y. Li M.D., Ph.D.	Executive VP & President of Merck Research Laboratories	1963
Mr. Dalton E. Smart III	Senior VP of Finance, Principal Accounting Officer & Global Controller	1967
Mr. Gaurav K. Gupta	Executive Vice President and Chief Information & Digital Officer	—
Mr. Peter Dannenbaum	Vice President of Investor Relations	—
Mr. Chirfi Guindo	Executive Vice President of Strategic Access, Policy & Communications	1966
Ms. Betty D. Larson	Executive VP & Chief Human Resources Officer	1976
Mr. Richard R. DeLuca Jr.	Executive VP & President of Merck Animal Health	1963

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-8.2	+3.0
2022	+6.0	-6.5	+7.5	+6.2	+5.0	+0.0	-3.3	-3.6	-1.2	+15.6	+10.4	+1.0
2023	-3.4	-0.7	-0.2	+6.1	-5.1	+4.0	-6.7	+3.5	-6.3	+0.1	-0.4	+5.4
2024	+6.7	+0.6	+3.9	-1.4	-2.5	-3.6	-11.5	+4.1	-2.6	-10.8	-0.2	-1.1
2025	-0.4	-7.6	-3.6	-2.2	-7.7	+3.8	-4.5	+6.1	-1.8	-4.6	+27.1	+3.4
2026	+3.6	+9.2	-0.9	-9.6	+5.8	+11.6	+3.9	+15.6	-3.0	+4.0	-2.5

Stocks in the same sector

FAQ

Buying Merck (MRK) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "MRK", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy MRK by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Merck from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Yes, Merck regularly pays dividends to shareholders. Currently, the estimated dividend yield for MRK is around 2.26% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Merck (MRK) Stock

Key stats

Compare with MRK

Recent news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

Merck gets US FDA emergency use nod for treatment of screwworm in dogs

Merck gets US FDA emergency use nod for treatment of screwworm in dogs

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.

Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

Merck gets US FDA emergency use nod for treatment of screwworm in dogs

Merck gets US FDA emergency use nod for treatment of screwworm in dogs

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.

Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.

Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026

Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

Moderna, Merck eye FDA approval for promising cancer vaccine

Moderna, Merck eye FDA approval for promising cancer vaccine

Why Merck Stock Flew Higher on Friday

Why Merck Stock Flew Higher on Friday

About Merck

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade